Dr Carlos Wong is currently an Assistant Professor at the Department of Pharmacology and Pharmacy and Department of Family Medicine and Primary Care of The University of Hong Kong. He obtained his PhD in quality of life ('Health-related Quality of Life of Chinese Patients with Colorectal Neoplasms') at the University of Hong Kong. Prior to his PhD, He received his Bachelor and MPhil degrees from Department of Mathematics at Hong Kong University of Science and Technology.

His current research interests are pharmacoepidemiology, and health services research, particularly retrospective administrative database research and cost-effectiveness analysis of health care interventions. He has published more than 250 articles in peer-reviewed journals including The Lancet, Nature Medicine, The Lancet Infectious Diseases, Annals of Internal Medicine, Journal of Hepatology, Diabetes Care, Clinical Infectious Diseases, EClinicalMedicine, PLOS Medicine, BMC Medicine, Annals of Surgery, etc. He was appointed as member of editorial board of journal 'The Patient - Patient-Centered Outcomes Research', and statistical advisor of 'Hong Kong Medical Journal'. Dr Carlos Wong was awarded the Glasgow / HKU early career mobility fund to be visiting researcher at Health Economics and Health Technology Assessment (HEHTA), University of Glasgow in 2016, and was received the HMRF Research Fellowship in 2017 to be academic visitor at Health Economics Research Centre, University of Oxford in 2019.

Office: 2/F, 21 Sassoon Road, Li Ka Shing Faculty of Medicine, Laboratory Block, Faculty of Medicine Building, Hong Kong SAR, China.

Memberships and Editorships

Memberships:

• Council Member, World Association for Chinese Quality of Life
• Member, EuroQol Group

Editorships:

• Editorial Board Member – The Patients – Patient-Centered Outcomes Research
• Statistical Editor – Hong Kong Medical Journal

Honours and Awards

• Hong Kong College of Family Physicians Best Research Award 2021 (with Dr Emily Tse) on the project ‘Non-laboratory-based Risk Assessment Model for Case Detection of Diabetes Mellitus and Pre-diabetes in Primary Care’
• Distinguished Research Paper Award for Young Investigators 2022 (with Dr David Lui) on the paper titled "Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis"
• HMRF 10-year Anniversary Award (with Prof Cindy Lam), Health Research Symposium, Food & Health Bureau, Hong Kong SAR, 2021
• Faculty Outstanding Research Output Award on the paper titled "Five-Year Effectiveness of the Multidisciplinary Risk Assessment and Management Programme-Diabetes Mellitus (RAMP-DM) on Diabetes-Related Complications and Health Service Uses-A Population-Based and Propensity-Matched Cohort Study" (with Dr Eric Wan, Dr Daniel Fong, Dr Colman Fung, Dr WY Chin, Dr Esther Yu, Prof Cindy Lam), Li Ka Shing Faculty of Medicine, University of Hong Kong, 2020
• Best Poster Award Finalist (Top 10% research poster presentations): International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual European Congress, Glasgow, UK; 2017
• Excellent Research Award, Health Research Symposium 2017: Health and Medical Research Fund, Food & Health Bureau, the Government of HKSAR; 2017
• Winner of Best Student Poster Presentation Award, 19th Annual Conference of the International Society for Quality of Life Research, Budapest Marriott, Budapest, Hungary, 2012
• Wong Ching Yee Medical Postgraduate Scholarships: The University of Hong Kong; 2011-2012
• Young QOL Researchers Scholarship: Hong Kong Society of Quality of Life; 2010
• Winner of Best Student Oral Presentation Award on 17th Annual Conference of the International Society for Quality of Life Research, London, United Kingdom; 2010

• Pharmacoepidemiology and health economics study
• Economic Evaluation and Cost-effectiveness Analysis of primary and secondary care interventions in Chinese population
• Psychometric Validation on generic and disease-specific Health-related Quality of Life instruments

Publications Highlights

Selected Publications

• Wong, C.K.H.*, et al. Optimal timing of remdesivir initiation in hospitalized COVID-19 patients administered with dexamethasone, Clinical Infectious Diseases, 2021, DOI:10.1093/cid/ciab728 [IF=20.999, JCR: 18/162 in Immunology, 3/92 in Infectious Diseases, 12/137 in Microbiology, corresponding author and first author]
• Wong, C.K.H.*, et al. Clinical improvement, outcomes, antiviral activity, and costs associated with early treatment with remdesivir for patients with COVID-19. Clinical Infectious Diseases 2022;74(8):1450-1458 DOI: 10.1093/cid/ciab631 [IF=20.999, JCR: 18/162 in Immunology, 3/92 in Infectious Diseases, 12/137 in Microbiology, corresponding author and first author]
• Tang, E.H.M., …, Wong, C.K.H.*, Lam, C.L.K. Ten-year effectiveness of multidisciplinary Risk Assessment and Management Programme - Diabetes Mellitus (RAMP-DM) on macrovascular, microvascular complications and all-cause mortality: A population-based cohort study. Diabetes Care 2022 [IF=17.152, co-corresponding author]
• Wong, C.K.H., et al. Clinical outcomes of different therapeutic options for COVID-19 in two Chinese case cohorts: a propensity-score analysis. EClinicalMedicine 2021;32:100743 [IF= 17.033, JCR: 12/172 in Medicine, General & Internal, co-first author]
• Lui, D.T.W., Au, I.C.H., … Wong, C.K.H.. Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis, EClinicalMedicine, 50, 101510. (2022), DOI: 10.1016/j.eclinm.2022.101510 [IF= 17.033, JCR: 12/172 in Medicine, General & Internal, corresponding author]
• Wong, C.K.H., et al. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study, PLoS medicine, 19(6), p.e1004018, DOI: 10.1371/journal.pmed.1004018 [IF=11.613, JCR: 20/167 in Medicine, General & Internal, co-first author]
• Wong, C.K.H., et al. Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unscheduled hospitalization. BMC Med 20, 119 (2022). DOI: 10.1186/s12916-022-02321-4 [IF=11.150, JCR: 21/172 in Medicine, General & Internal, co-first author]
• Liu, X., Wong, C.K.H., et al. Outcomes of Graves’ disease patients following anti-thyroid drugs, radioactive iodine or thyroidectomy as the first-line treatment. Annals of Surgery 2021;273(6):1197-1206. [IF= 13.787, JCR= 2/211 in Surgery, co-first author]
• Liu, X., Wong, C.K.H., et al. Long-term outcome of patients treated with antithyroid drugs, radioactive iodine or surgery for persistent or relapsed Graves’ disease, British Journal of Surgery 2022;109(4):381-389 [IF=11.122, JCR: 11/211 in Surgery, First author]
• Wu, T., ..., Wong, C.K.H., Bariatric surgery is expensive but improves comorbidity: Five-year assessment of patients with obesity and type 2 diabetes. British Journal of Surgery 2021;108(5):554-565 [IF=11.122, JCR: 11/210 in Surgery, corresponding author]

Funding

Principal Investigator in External Competitive Grants

• 2021-2023 Psychometric properties of EQ-5D-5L for use in patients with autoimmune Graves' disease. EQ project 3330RA, EuroQol Research Foundation. (EUR29,400)
• 2020-2023 Long-term impact of thyroidectomy on effectiveness and cost-effectiveness for relapsed Graves’ disease. Health and Medical Research, Food and Health Bureau. (HK$ 1,186,959)
• 2020-2021 Effectiveness of single and combined anti-COVID-19 drugs among hospitalized COVID-19 patients in Hong Kong. Commissioned Research on COVID-19, Food and Health Bureau. (HK$ 482,960)
• 2019-2020 Psychometric testing of proxy EQ-5D-5L-Y in caregivers of paediatric patients with idiopathic scoliosis. Euroqol Research Foundation. (HK$ 64,500)
• 2019-2020 Agreement between proxy EQ 5D Y and self reported EQ 5D Y in a paediatric patient group. Euroqol Research Foundation. (HK$ 45,000)
• 2019-2021 Elicitation of health state utilities for paediatric populations from the general public. General Research Fund. (HK$ 968,347)
• 2017-2019 A cost-effectiveness threshold of body mass index for undergoing bariatric surgery for obese patients. Health and Medical Research Fund Research Fellowship Scheme, Food and Health Bureau. (HK$ 1,166,684)
• 2016-2017 Cost and Cost-effectiveness Analysis of Renal Replacement Therapy Modalities for Patients with End-stage Renal Disease in Hong Kong: Comparison between Peritoneal Dialysis and Haemodialysis Strategies. Health and Medical Research Fund, Food and Health Bureau. (HK$526,952) Completed with final report graded as ‘5-excellent’
  

Office

2/F, 21 Sassoon Road, Li Ka Shing Faculty of Medicine, Laboratory Block, Faculty of Medicine Building, Hong Kong SAR, China